Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020999 | 0.95 | TSHR (0.32) | TSHR | |
| SCHEMBL14858101 | 0.93 | PDE7B (0.31) | TSHR | |
| SCHEMBL104600 | 0.90 | — | — | |
| SCHEMBL13143433 | 0.79 | EPHX1 (0.34) | — | |
| SCHEMBL1111457 | 0.76 | TDP1 (0.33) | — | |
| SCHEMBL1111492 | 0.76 | TDP1 (0.33) | — | |
| SCHEMBL17476207 | 0.76 | PDE7B (0.34) | — | |
| SCHEMBL3687892 | 0.76 | USP2 (0.30) | TSHR | |
| SCHEMBL2633895 | 0.75 | USP2 (0.35) | TSHR | |
| SCHEMBL17476206 | 0.75 | PDE7B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-9981954-B2 | 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | CNR1, CNR2, SIGMAR1 | TSHR 80/4885CDC25A 3905/4885CDC25B 3743/4885 |
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | SCNN1A, TRPV1, SCNN1B | TSHR 1235/4885CDC25A 1322/4885CDC25B 2966/4885 |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | TSHR 4115/4885CDC25A 390/4885CDC25B 403/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | TSHR 4115/4885CDC25A 390/4885CDC25B 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.